glp 1 agonist saxenda Novo Nordisk announces Saxenda® (liraglutide [rDNA origin] injection) is now commercially available in the United States Oral GLP-1 weight loss medication

Moreover, given the high cost of these medications and the limited access for uninsured, underinsured, or low-income individualswho may stand to benefit the mostthere is a critical need for policies that enhance access to these therapies to mitigate potential health disparities

For each kilogram of peptide drug, dozens of kilograms of solvent waste may be produced

However, the native GLP-1 peptide does not seem to be suitable for long-term treatment of patients with type 2 diabetes mellitus, primarily owing to its low stability in vivo

Lancet 375 , 22342243 (2010)

This surge reflects a paradigm shift in how we approach diabetes and obesity management

142 This has important implications for individuals with IBD, as delayed gastric transit may impair the absorption of orally administered therapies such as 5-ASA and thiopurines